1
ALL1
Softigel ProcapsYear
1
ALL1
2021DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
COLOMBIA1
ALL1
SciSparcTherapeutic Area
1
ALL1
Psychiatry/PsychologyStudy Phase
1
ALL1
Phase IIDeal Type
1
ALL1
CollaborationProduct Type
1
ALL1
Small moleculeDosage Form
1
ALL1
capsuleLead Product
1
ALL1
TetrahydrocannabinolTarget
1
ALL1
CB1 receptorLead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : SciSparc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : SCI-110 is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous system.
Brand Name : SCI-110
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : SciSparc
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?